Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Arcutis Biotherapeutics Inc
Revenue
Arcutis Biotherapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
Revenue
$59.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$29.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
Arcutis Biotherapeutics Inc
Revenue Breakdown
Breakdown by Geography
Arcutis Biotherapeutics Inc
Breakdown by Segments
Arcutis Biotherapeutics Inc
Total Revenue:
59.6m
USD
|
Other Revenue:
30.4m
USD
|
Product:
29.2m
USD
|
See Also
What is Arcutis Biotherapeutics Inc's Revenue?
Revenue
59.6m
USD
Based on the financial report for Dec 31, 2023, Arcutis Biotherapeutics Inc's Revenue amounts to 59.6m USD.
What is Arcutis Biotherapeutics Inc's Revenue growth rate?
Revenue CAGR 1Y
1 515%
Over the last year, the Revenue growth was 1 515%.